On Wednesday, Shares of Gilead Sciences Inc. (NASDAQ:GILD), gained 0.20% to $98.39.
Gilead Sciences, has YTD performance of 3.27%. The company has the market capitalization of $144.10B while its P/B ratio was 8.90. Institutional investors own 83.40% stake in the company while beta factor, which is used to measure riskiness of the security, was 0.81. Net profit margin of this company was 51.50% while its operating profit margin was 64.40%.
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in areas of unmet medical need in North America, South America, Europe, and the Asia-Pacific.
Shares of Intrexon Corporation (NYSE:XON), inclined 2.96% to $33, during its last trading session.
Intrexon Corporation (XON), a leader in synthetic biology, recently declared that ViaGen Pets, a partner of the Company which actively serves pet owners seeking genetic preservation services for their beloved companion animals, has successfully delivered two litters of healthy, cloned kittens for its clients. With its recently accomplished state-of-the-art lab offering unprecedented capabilities, ViaGen Pets is preparing for a global launch of its services in early 2016 providing an opportunity to pet owners worldwide that has never before existed.
“I couldn’t be more happy with the birth of these adorable kittens,” noted Blake Russell, President of ViaGen Pets. “As the largest global provider of genetic preservation services for companion animals, we look forward to expanding the life-enriching connections that people form with their pets. Our aim is to bring this opportunity to all pet owners and their families.”
Through the combination of Intrexon’s expertise in reproductive technologies and ViaGen’s experience as the trusted world leader in cloned mammals for over 15 years, more affordable options for those who wish to preserve the genetics of their beloved companion animals is near. ViaGen Pets presently has clients across multiple countries that have trusted the Company to deliver a genetic twin of their puppies and kittens and is actively engaging the global veterinary community recently as it develops partnerships to best serve the pet owner.
Intrexon Corporation, a biotechnology company, operates in the synthetic biology field in the United States. The company, through a suite of proprietary and complementary technologies, designs, builds, and regulates gene programs, which are DNA sequences that comprise of key genetic components.
Finally, Dyax Corp. (NASDAQ:DYAX), ended its last trade with 3.92% gain, and closed at $23.57.
Dyax Corp., will host a webcast and conference call, counting an open question and answer session, Wednesday, October 28, 2015. During the call, administration will discuss the Company’s financial results for the third quarter 2015 in addition to progress regarding its key value drivers – DX-2930, the KALBITOR® (ecallantide) business and the Licensing and Funded Research Portfolio (LFRP).
Dyax Corp., a biopharmaceutical company, identifies, develops, and commercializes treatments for hereditary angioedema (HAE) and other plasma-kallikrein-mediated (PKM) disorders. It offers KALBITOR for the treatment of acute attacks of HAE.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties, which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified with such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should/might occur.
